litlas
ログインアカウント作成

Hiroji Iwata

1996–2025 年に発表

226
論文数
47,914
被引用数
89
h 指数
213
i10 指数

被引用数

Hiroji Iwata の年別被引用数1964 年: 被引用 2 件1971 年: 被引用 1 件1993 年: 被引用 2 件1996 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 10 件1999 年: 被引用 12 件2000 年: 被引用 6 件2001 年: 被引用 12 件2002 年: 被引用 12 件2003 年: 被引用 15 件2004 年: 被引用 20 件2005 年: 被引用 20 件2006 年: 被引用 73 件2007 年: 被引用 109 件2008 年: 被引用 107 件2009 年: 被引用 120 件2010 年: 被引用 136 件2011 年: 被引用 106 件2012 年: 被引用 116 件2013 年: 被引用 144 件2014 年: 被引用 107 件2015 年: 被引用 139 件2016 年: 被引用 232 件2017 年: 被引用 237 件2018 年: 被引用 308 件2019 年: 被引用 1,327 件2020 年: 被引用 2,262 件2021 年: 被引用 2,847 件2022 年: 被引用 2,710 件2023 年: 被引用 2,304 件2024 年: 被引用 3,188 件2025 年: 被引用 1,586 件2026 年: 被引用 40 件1965〜1970 年は被引用が無いため表示していません1972〜1992 年は被引用が無いため表示していません1994〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,754 件、この内訳の 22.3%中国: 引用元論文 2,375 件、この内訳の 11.1%イタリア: 引用元論文 1,304 件、この内訳の 6.1%イギリス: 引用元論文 1,170 件、この内訳の 5.5%ドイツ: 引用元論文 987 件、この内訳の 4.6%フランス: 引用元論文 893 件、この内訳の 4.2%スペイン: 引用元論文 827 件、この内訳の 3.9%日本: 引用元論文 771 件、この内訳の 3.6%カナダ: 引用元論文 747 件、この内訳の 3.5%オーストラリア: 引用元論文 608 件、この内訳の 2.9%韓国: 引用元論文 527 件、この内訳の 2.5%ベルギー: 引用元論文 514 件、この内訳の 2.4%
0%22.3%その他 27.4%

機関

分野

  • Medicine63.9%
  • Biochemistry, Genetics and Molecular Biology27.9%
  • Immunology and Microbiology3.2%
  • Engineering1.1%
  • Materials Science1%
  • Computer Science0.9%
  • その他2%

トピック

  • HER2/EGFR in Cancer Research8.7%
  • Advanced Breast Cancer Therapies7.3%
  • Breast Cancer Treatment Studies6.5%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Cancer Genomics and Diagnostics3%
  • Monoclonal and Polyclonal Antibodies Research2.8%
  • その他65.3%

共著者

全論文

検索で開く
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    著者: Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Roberto Hegg, Seock‐Ah Im, Gail S. Wright, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - New England Journal of Medicine 2018 被引用: 4,369

  2. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    著者: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 被引用: 2,572

  3. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    著者: Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung‐Bae Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock‐Ah Im, Keun Seok Lee, Sara A. Hurvitz, Javier Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian E. Krop - New England Journal of Medicine 2019 被引用: 1,973

  4. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    著者: Javier Cortés, Hope S. Rugo, David W. Cescon, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, José Manuel Pérez-García, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Xuan Zhou, Vassiliki Karantza, Wilbur Pan, Peter Schmid - New England Journal of Medicine 2022 被引用: 1,096

  5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    著者: Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, F. Vidal Luis, Gomez Abuin Gonzalo, Diego Kaen, Kowalwszyn Ruben, Molina Matias, Varela Mirta, Sally Baron-Hay, Begbie Stephen, Clingan Philip, Loi Sherene, Sabanathan Dhanusha, Andrea Gombos, Donatienne Taylor, Carlos Barrios, Leandro Brust, Costa Fabiano, de Freitas Junior Ruffo, Roberto Hegg, Lacerda Domicio Carvalho, Lissa Fernando Cezar Toniazzi, Rocha Roberto Odebrecht, Scalabrini Neto Antonio Orlando, Silva Felipe, Cescon David, Danielle Charpentier, Ferrario Cristiano, Xinni Song, Yu Joanne, Alejandro Acevedo, Gallardo Carlos, Salas Claudio, Sanchez Cesar, Eduardo Yañez, Gomez Diaz Alvaro, Sanchez Jesus, Holeckova Petra, Kral Zdenek, Bohuslav Melichar, Katarína Petráková, Prausova Jana, Vesna Glavicic, Jakobsen Erik, Jensen Jeanette, Søren Linnet, Tamás Lörincz, Bonnefoi Herve, Isabelle Desmoulins, Goncalves Anthony, Hardy-Bessard Anne-Claire, Luís Teixeira, Blohmer Jens-Uwe, Fasching Peter, Dirk Forstmeyer, Nadia Harbeck, Huober Jens, Kaczerowsky Flores de Sousa Anna, Kurbacher Christian, Sibylle Loibl, Lueftner Diana, Park-Simon Tjoung-Won, Schumann Raquel Von, Pauline Wimberger, Chow Louis, Kwong Ava, Ngan Kai Cheong Roger, Peter Arkosy, Tibor Csőszi, Zsuzsanna Kahán, Landherr László, Mahr Karoly, Gábor Rubovszky, Crown John, Kelly Catherine, O'Reilly Seamus, Saverio Cinieri, DAlessio Antonietta, Ricevuto Enrico, Tomoyuki Aruga, Takaaki Fujii, Inoue Kenichi ほか 127 名 - The Lancet 2020 被引用: 1,800

  6. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    著者: Javier Cortés, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Chiun-Sheng Huang, Jee Hyun Kim, Joanne W.Y. Chiu, Jose Luiz Pedrini, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz - New England Journal of Medicine 2022 被引用: 1,124

  7. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    著者: Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, Seock‐Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altıntaş, Jan‐Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Sung‐Bae Kim, Vanessa Petry, Chiun‐Sheng Huang, Wěi Li, Jean‐Sébastien Frenel, Silvia Antolín, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés - The Lancet 2022 被引用: 642

  8. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

    著者: Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, Jane Yuet Ching Hui, Nadia Harbeck - The Lancet 2020 被引用: 1,060

  9. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

    著者: Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young‐Hyuck Im, Eun Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock‐Ah Im, Byeong‐Woo Park, Sung‐Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong Hwa Park, Hironobu Sasano, Yasuo Ohashi, Masakazu Toi - New England Journal of Medicine 2017 被引用: 1,887

  10. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - The Lancet Oncology 2019 被引用: 1,198

  11. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

    著者: Shanu Modi, Haeseong Park, Rashmi K. Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno‐Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles H. Redfern, Ian E. Krop, Caleb Lee, Yoshihiko Fujisaki, Masahiro Sugihara, Lin Zhang, Javad Shahidi, Shunji Takahashi - Journal of Clinical Oncology 2020 被引用: 817

  12. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    著者: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 被引用: 1,822

  13. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    著者: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 被引用: 1,293

  14. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

    著者: Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Shilpen Patel, S.Y. Chui, P. Schmid - Annals of Oncology 2021 被引用: 468

  15. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    著者: Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli - New England Journal of Medicine 2015 被引用: 1,586

  16. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    著者: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 被引用: 599

  17. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

    著者: Stephen Johnston, Miguel Martín, Angelo Di Leo, Seock‐Ah Im, Ahmad Awada, Tammy Forrester, Martin Frenzel, Molly Catherine Hardebeck, Joanne Cox, Susana Barriga, Masakazu Toi, Hiroji Iwata, Matthew P. Goetz - npj Breast Cancer 2019 被引用: 676

  18. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

    著者: Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 被引用: 5,098

  19. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

    著者: Junji Tsurutani, Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles H. Redfern, Kenji Tamura, Trisha M. Wise‐Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li - Cancer Discovery 2020 被引用: 353

  20. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

    著者: Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis, Rita Nanda, Eric P. Winer, Hirofumi Mukai, Kenji Tamura, Anne Armstrong, M.C. Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, Hope S. Rugo, Antoinette R. Tan, Lin Jia, Yu Ding, Vassiliki Karantza, Peter Schmid - Annals of Oncology 2018 被引用: 631

  21. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

    著者: Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Véronique Dièras, Hiroji Iwata, Carlos H. Barrios, M. Nechaeva, Anh Nguyen‐Duc, Jane Yuet Ching Hui, Amreen Husain, Eric P. Winer, Sylvia Adams, Peter Schmid - JNCI Journal of the National Cancer Institute 2021 被引用: 306

  22. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

    著者: Charles A. Powell, Shanu Modi, Hiroji Iwata, Shunji Takahashi, Egbert F. Smit, Salvatore Siena, D.-Y. Chang, E. Macpherson, A. Qin, Jasmeet Singh, Corina Taitt, Norah J. Shire, D. Ross Camidge - ESMO Open 2022 被引用: 231

  23. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

    著者: Kenji Tamura, Junji Tsurutani, Shunji Takahashi, Hiroji Iwata, Ian E. Krop, Charles H. Redfern, Yasuaki Sagara, Toshihiko Doi, Haeseong Park, Rashmi K. Murthy, Rebecca Redman, Takahiro Jikoh, Caleb Lee, Masahiro Sugihara, Javad Shahidi, Antoine Yver, Shanu Modi - The Lancet Oncology 2019 被引用: 350

  24. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

    著者: Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O’Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner - Clinical Cancer Research 2022 被引用: 198